Prostaglandin D₂ activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on T\(_H\)2 cells

Luzheng Xue, PhD, a, *, Maryam Salimi, MD, a, b, * Isabel Panse, BTA, c Jenny M. Mjöberg, PhD, c Andrew N. J. McKenzie, PhD, d Hergen Spits, PhD, a Paul Kleneman, F Med Sci, a, d and Graham Ogg, DPhil, FRCPa, b, f

Oxford and Cambridge, United Kingdom, Stockholm, Sweden, and Amsterdam, The Netherlands

Background: Activation of the group 2 innate lymphoid cell (ILC2) population leads to production of the classical type 2 cytokines, thus promoting type 2 immunity. Chemoa attractant receptor-homologous molecule expressed on T\(_H\)2 cells (CRTH2), a receptor for prostaglandin D\(_2\) (PGD\(_2\)), is expressed by human ILC2s. However, the function of CRTH2 in these cells is unclear. Objectives: We sought to determine the role of PGD\(_2\) and CRTH2 in human ILC2s and compare it with that of the established ILC2 activators IL-25 and IL-33.

Methods: The effects of PGD\(_2\), IL-25, and IL-33 on the cell migration, cytokine production, gene regulation, and receptor expression of ILC2s were measured with chemotaxis, ELISA, Luminex, flow cytometry, quantitative RT-PCR, and QuantiGene assays. The effects of PGD\(_2\) under physiologic conditions were evaluated by using the supernatant from activated mast cells.

Results: PGD\(_2\) binding to CRTH2 induced ILC2 migration and production of type 2 cytokines and many other cytokines. ILC2 activation through CRTH2 also upregulated the expression of IL-33 and IL-25 receptor subunits (ST2 and IL-17RA). The effects of PGD\(_2\) on ILC2s could be mimicked by the supernatant from activated human mast cells and inhibited by a CRTH2 antagonist.

Conclusions: PGD\(_2\) is an important and potent activator of ILC2s through CRTH2 mediating strong proallergic inflammatory responses. Through IgE-mediated mast cell degranulation, these innate cells can also contribute to adaptive type 2 immunity; thus CRTH2 bridges the innate and adaptive pathways in human ILC2s. (J Allergy Clin Immunol 2014;133:1184-94.)

Key words: Group 2 innate lymphoid cell, PGD\(_2\), chemoattractant receptor-homologous molecule expressed on T\(_H\)2 cells, IL-25, IL-33, innate type 2 immunity, adaptive type 2 immunity

Innate lymphoid cells (ILCs) are emerging as a novel family of hematopoietic effectors that are heterogeneous in their location, cytokine production, and effector functions. They lack specific antigen receptors and lineage markers and serve critical roles in innate immune responses to microorganisms, lymphoid tissue formation, and tissue remodeling. ILCs can be categorized into 3 subsets (group 1 ILCs [ILC1s], group 2 ILCs [ILC2s], and group 3 ILCs [ILC3s]) based on phenotypic and functional characteristics.

ILC2s are ILCs that produce type 2 cytokines (IL-4, IL-5, IL-9, and IL-13) and are dependent on GATA3 and retinoic acid receptor–related orphan receptor α for their development and function. This group of cells is found in the blood, spleen, intestine, liver, skin, fat-associated lymphoid clusters, and lymph nodes of mice and have also previously been termed natural helper cells, nuocytes, or innate helper 2 cells by different groups, but the overall term ILC2 is now accepted. They express IL-17RB (IL-25R) and ST2 (IL-17RA) receptors and respond to IL-25 (IL-17 family member) and IL-33 (IL-1 family member). Such cells are thought to contribute to protection against parasites and also promote allergic inflammation. Lung-resident ILC2s in mice have been shown to restore epithelial integrity and lung function by producing amphiregulin, a wound-healing regulator. Airway infection with H3N1 induced airway hyperreactivity by stimulating alveolar macrophages to produce IL-33 and therefore activating ILC2s. Similarly,
intrasal administration of IL-25 and IL-33 in mouse asthma models induces ILC2 infiltration into the lungs and airway hyperreactivity. The human counterpart of mouse ILC2s was recently discovered in human peripheral blood, lung tissue, and fetal gut and skin and has been found in increased numbers in inflamed nasal polyps and skin. ILC2s observed within lesional atopic dermatitis skin is compatible with a role in pathogenesis because increased production of IL-13 is well established in atopic skin, leading to downregulation of antimicrobial peptides and filaggrin. This human ILC population was found also to express chemoattractant receptor-homologous molecule expressed on T cells (CRTH2). A recent report showed that prostaglandin D$_2$ (PGD$_2$) induced ILC2s to produce IL-13 through activation of CRTH2 in a synergistic manner with IL-25/IL-33. However, understanding of the role of CRTH2 in ILC2s is still limited.

CRTH2 is a G protein–coupled receptor for PGD$_2$, a major mediator released from activated mast cells. Before the discovery of ILC2s, CRTH2 was known to be abundant on eosinophils, basophils, and T$_{H}$2 cells. Emerging evidence suggests that the activation of CRTH2 leads to proinflammatory responses in leukocytes, including chemotaxis of eosinophils, basophils, and T$_{H}$2 cells; T$_{H}$2 cytokine production, which is enhanced by cysteinyl leukotrienes (cysLTs) and proinflammatory protein expression. Our previous studies also demonstrated that the signaling of CRTH2 suppresses T$_{H}$2 cell apoptosis. Allergic responses mediated by IgE, mast cells, and eosinophils are dramatically reduced in mice in which CRTH2 is genetically ablated or by small-molecule CRTH2 antagonists. Antagonism of CRTH2 is currently being tested as a useful approach to control allergic diseases.

In this study we investigated the role of CRTH2 in human ILC2s isolated ex vivo. We found that CRTH2 plays a critical role in proinflammatory responses of ILC2s, including cell migration and diverse cytokine production. Activation of CRTH2 also upregulated the IL-33 and IL-25 receptors (ST2 and IL-17RA), and the combination of PGD$_2$, IL-33, and IL-25 enhanced some ILC2 responses. These novel observations define CRTH2 as a key trigger for ILC2 activation and thus places it at the center of a tissue inflammation network.

**METHODS**

**ILC2 cell preparation and culture**

Skin immune cells were isolated from the human skin biopsy specimens of healthy donors. The tissue was cut and then digested in collagenase at 37°C overnight. After washing with 10 mM EDTA solution, cell suspensions were obtained by passing through tissue strainers. Mononuclear cells were isolated from the cell suspensions with Ficoll-Paque PLUS gradient. PBMCs were obtained by passing through tissue strainers. Mononuclear cells were incubated with human IgE (Chemicon International, Temecula, Calif) and goat anti-human IgE (Chemicon International, Temecula, Calif) in the presence or absence of diclofenac (10 μmol/L), as described previously. Supernatants of the cells were collected and measured for PGD$_2$ and IL-13 with ELISA or stored at −80°C until used as mast cell supernatants for the treatment of ILC2s.

**Chemotaxis assays**

For measurement of cell migration, ILC2s were resuspended with RPMI 1640 media; 25 μL of cell suspension and 29-μL test samples prepared in RPMI 1640 or mast cell supernatants were applied to the upper and lower chambers, respectively, in a 5-μm pore sized 96-well Chemotx plate (Neuro Probe, Gaithersburg, Md). After incubation (37°C for 60 minutes), the migrated cells in the lower chambers were collected and mixed with a Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis) and quantified by using a FLUOstar OPTIMA luminescence plate reader (BMG LabTech, Cary, NC).

**Luminex assays**

After ILC2 treatments for 4 hours, the concentrations of selected human cytokines in the supernatants were measured by using a Procarta Human Cytokine Immunoassay kit (Affymetrix, Santa Clara, Calif) with magnetic beads, according to the manufacturer’s instruction. Results were obtained with a Bio-Plex 200 System (Bio-Rad Laboratories, Hercules, Calif).

**QuantiGene Plex assays**

After various treatments for 2.5 hours, the mRNA levels of selected genes in ILC2s were measured by using a QuantiGene 2.0 Plex Assay kit (Affymetrix) with magnetic beads, as per the manufacturer’s instruction. Results were quantified with a Bio-Plex 200 System (Bio-Rad Laboratories).

**Quantitative RT-PCR**

Quantitative RT-PCR was conducted, as described previously. Primers and probes (Roche, Mannheim, Germany) used are listed in Table E2 in this article’s Online Repository at www.jacionline.org.

**ELISA**

Concentrations of cytokines in the supernatants of ILC2s or mast cells were assayed with ELISA kits (R&D Systems, Minneapolis, Minn). PGD$_2$ levels in the supernatants of mast cells were assayed with a PGD$_2$-MOX enzyme-linked...
immunoassay kit (Cayman Chemicals, Ann Arbor, Mich). Results were measured in a FLUOstar OPTIMA luminescence plate reader (BMG LabTech).

**Flow cytometric analysis**

ILC2s were fluorescently labeled with antibodies (see Table E1) and acquired by using Summit software on a CyAn flow Cytometer (Beckman Coulter).

**Statistics**

Data were analyzed by using 1-way ANOVA, followed by the Newman-Keuls test. *P* values of less than .05 were considered statistically significant.

**RESULTS**

**CRTH2 mediates chemotaxis of human ILC2s**

To understand the role of CRTH2 in human ILC2s, we compared the effect of PGD2 with the effects of IL-33 and IL-25 on ILC2 migration. Lineage-negative, CD45 high, CD127+, and CRTH2+ ILC2s were isolated from human skin biopsy specimens and peripheral blood of healthy adult donors (Fig 1 and see Fig E1 in this article’s Online Repository at www.jacionline.org) and tested with dose titrations of PGD2, IL-33, and IL-25 in chemotaxis assays (Fig 2, A). Both PGD2 and IL-33 caused ILC2 migration in a dose-dependent manner, peaking at approximately 100 nmol/L for PGD2 and 30 ng/mL for IL-33. The chemoattractant effect of IL-25 on ILC2s was very weak. The maximum response achieved with PGD2 was 4.75-fold higher than that achieved with IL-33. The ILC2s cultured from skin and blood showed similar responses to PGD2, IL-25, and IL-33.

To confirm the receptor mediating ILC2 migration induced by PGD2 was CRTH2, we used the selective CRTH2 antagonist TM30089. ILC2 migration triggered by PGD2 (30 nmol/L) was completely inhibited by TM30089 (1 μmol/L; Fig 2, B).

The effects of combinations of these stimulators were examined to further elucidate the contribution and interaction of PGD2, IL-33, and IL-25 on ILC2 migration (Fig 2, C). Concentrations of stimulators less than the peak in their dose curves (5 nmol/L for PGD2 and 10 ng/mL for IL-33 and IL-25) were used for these combination tests to avoid saturation of the response. No additive effect was detected when the stimulators were combined. The cell migration in response to the combinations of PGD2 and IL-33 or PGD2, IL-33, and IL-25 at these doses appeared to be mainly mediated by CRTH2 because the responses were largely inhibited by TM30089.

**Activation of human ILC2s through CRTH2 induces type 2 cytokine production**

One of the most striking features of ILC2s is their ability to produce type 2 cytokines.5 Cells were stimulated with increasing concentrations of PGD2 for 2.5 hours for mRNA analysis or for 4 hours for protein analysis to investigate the role of CRTH2 in type 2 cytokine production in human ILC2s (Fig 3, A). The treatment increased cytokine expression at the levels of both mRNA and secreted protein in a dose-dependent manner (Fig 3, A). The median effective concentration (EC50) of PGD2 for IL-4, IL-5, and IL-13 production at the mRNA level was 88, 178, and 111 nmol/L, respectively, and that at the protein level was 195, 118, and 82.6 nmol/L, respectively. Type 2 cytokine production induced by 100 nmol/L PGD2 was completely blocked with 1 μmol/L TM30089 (Fig 3, B).

It has been reported that IL-33 and IL-25 promote type 2 cytokine production from ILC2s.5,38,39 ILC2s were treated with PGD2, IL-33, or IL-25 alone (at concentrations close to their relative EC50) or in combination for 4 hours to define the effect of the combination of PGD2, IL-33, and IL-25 on type 2 cytokine production (Fig 3, B). Both IL-33 and IL-25 evoked type 2 cytokine production from ILC2s. In contrast, IL-33 had no effect on Lin−CD127+CRTH2− cells (see Fig E2 in this article’s Online Repository at www.jacionline.org). However, the efficacy of both IL-33 and IL-25 at this time point was weaker than that of PGD2 in ILC2s from both skin and blood. Interestingly, the combination of IL-33 and IL-25 at these doses did not enhance stimulation compared with either IL-33 or IL-25 alone; however, the combination of these cytokines, particularly IL-25 with PGD2, enhanced cytokine production with an apparent synergistic effect.
The contribution of PGD2 in these combination treatments was effectively blocked by TM30089.

Activation of human ILC2s through CRTH2 regulates other cytokine production

The effect of CRTH2 on other cytokine production was investigated to further understand the proinflammatory role of CRTH2 in ILC2s (Fig 4). Cells were incubated with increasing concentrations of PGD2 for 4 hours, and protein levels of IL-3, IL-8, IL-9, IL-17A, IL-17F, IL-21, GM-CSF, macrophage colony-stimulating factor (CSF-1), and IFN-γ were measured. PGD2 induced the production of IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1 in a dose-dependent manner (Fig 4, A). The EC50 of PGD2 for IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1 was 79.8, 65.7, 47.4, 43, 132.5, and 29.2 nmol/L, respectively. No IL-17A, IL-17F, or IFN-γ was detected (data not shown). As for type 2 cytokines, the production of IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1 induced by PGD2, both at mRNA and protein levels, was enhanced by combination with IL-33 and IL-25. This enhancement was particularly significant for IL-8, IL-9, and GM-CSF production (Fig 4, A). In contrast, the mRNA level of IFN-γ was downregulated by PGD2 at nanomolar concentrations (Fig 4, C). The regulatory effects of PGD2 on these cytokines, whether activating or inhibitory, were reversed by TM30089 (1 μmol/L; Fig 4, B and C).

PGD2 upregulates IL-33 receptors but downregulates CRTH2 expression in human ILC2s

To explore the potential interaction between IL-33/IL-25–mediated and PGD2-mediated immune responses, we examined the effect of these activators on the expression of their receptors in ILC2s (Fig 5). After 2.5 hours of stimulation with PGD2, mRNA levels for ST2 were increased significantly, mRNA levels for the IL-17RA subunit of the IL-25 receptor were also upregulated slightly, and mRNA levels for CRTH2 were reduced markedly (Fig 5, A, and see Fig E3 in this article’s Online Repository at www.jacionline.org). The effect on the expression of the IL-17RB subunit of the IL-25 receptor was minor. Treatment with IL-33 or IL-25 alone had no significant effect on the expression of these receptors at this time point; however, the combination of PGD2, IL-33, and IL-25 enhanced the upregulation of ST2 mRNA (Fig 5, A). The CRTH2-dependent regulation of these receptors was inhibited by TM30089.

To verify the regulation of these receptors at the protein level, the expression of ST2 and CRTH2 on the cell surface of ILC2s was analyzed by using fluorescence-activated cell sorting after treatment with PGD2 (150 nmol/L) in the presence or absence of TM30089 (1 μmol/L; Fig 5, B and C). ST2-positive cells increased from 14.3% to 25.2% after 4 hours of treatment with PGD2, and this was inhibited by TM30089 (Fig 5, B). Decreased expression of CRTH2 was detected after 6 hours of treatment with PGD2, and the blockade of CRTH2 activity by using TM30089 inhibited this downregulation (Fig 5, C).

Human mast cell–derived PGD2 triggers ILC2s through CRTH2

Mast cells are the major source of PGD2 during allergic responses. The effect of endogenously synthesized PGD2 from activated human mast cells on ILC2s was examined to confirm the activation of CRTH2 in ILC2s under physiologic conditions.
conditions. Only low levels of PGD$_2$ (<0.1 ng/2$\times$10$^6$ cell/mL) were detectable in supernatants from resting mast cells. After activation with IgE followed by anti-IgE antibody cross-linking, mast cell cultures produced high PGD$_2$ levels (>11 ng/2$\times$10$^6$ cell/mL; Fig 6, A). Cotreatment of IgE/anti-IgE–activated mast cells with diclofenac (10$\mu$mol/L), an inhibitor of COX-2, during the period of anti-IgE stimulation abolished PGD$_2$ production (<0.2 ng/2$\times$10$^6$ cell/mL; Fig 6, A). Only very low levels of IL-13 (<200 pg/2$\times$10$^6$ cell/mL) could be detected in any of these mast cell supernatants.

The supernatants of these mast cell treatments were used to test the effects of endogenous PGD$_2$ in human ILC2s. Notably, the capacities of the supernatants to activate ILC2s were dependent on the PGD$_2$ levels in the supernatants (Fig 6 and see Fig E4 in this article’s Online Repository at www.jacionline.org). The supernatant containing high levels of PGD$_2$ (supernatant 2) but not the supernatant derived from the resting mast cells (supernatant 1) induced strong cell migration (Fig 6, B) and type 2 cytokine production (Fig 6, C). Treatment of ILC2s with supernatant 2 also caused the production of other proinflammatory cytokines (IL-3, IL-9, IL-21, GM-CSF, and CSF-1; see Fig E4). Blockade of PGD$_2$ synthesis with diclofenac (supernatant 3) removed most of the capacity to stimulate ILC2s, particularly for type 2 cytokines (Fig 6, B and C), although the effect of diclofenac on production of IL-3, IL-9, and CSF-1 was not significant (see Fig E4). These ILC2 cell responses to supernatant 2 were blocked by TM30089 (Fig 6, B and C, and see Fig E4). BWA868C, an antagonist for D prostanoid receptor (another PGD$_2$ receptor), and montelukast, an antagonist for cysteinyl leukotriene receptor 1 (CysLT$_1$), were used to further confirm the receptor involved (see Fig E5 in this article’s Online Repository at www.jacionline.org). Montelukast, but not BWA868C, inhibited production of IL-3, IL-9, and GM-CSF significantly in ILC2s in response to supernatant 2, and combination of TM30089 and montelukast blocked the response completely.

Similar to the results from experiments with exogenous PGD$_2$, the supernatant from activated mast cells upregulated the mRNA of ST2 mRNA significantly and IL-17RA weakly and downregulated CRTH2 mRNA in ILC2s (Fig 6, D). These effects were also inhibited by TM30089.

**DISCUSSION**

Activation of group 2 ILCs leads to the production of classical type 2 cytokines, thus promoting type 2 immunity. Increased numbers of ILC2s have been observed in inflamed tissues, such as allergic lung tissue in mice and nasal polyps $^{19}$ and skin $^{21}$ in
human subjects. It has been recently shown that CRTH2 is expressed in human ILC2s and that the activation of this receptor leads to IL-13 release from the cells. Here we have shown that PGD$_2$ elicits many strong proinflammatory responses in ex vivo ILC2s isolated from human skin and blood. In contrast to Kim et al. who did not identify CD161$^+$CRTH2$^+$ ILC2s in healthy human skin, we managed to isolate these cells from the normal human skin, although they were in low proportion. PGD$_2$ induced migration of these cells and promoted production of type 2 cytokines (IL-4, IL-5, and IL-13) and many other proinflammatory
cytokines (IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1). The stimulatory effect of PGD2 was mediated by CRTH2 because it was inhibited completely by a specific CRTH2 antagonist TM30089. These proinflammatory roles of CRTH2 in ILC2s could be confirmed under pathophysiologic conditions by using endogenously synthesized PGD2 from human mast cells activated through IgE binding. Therefore our study reveals a potent mechanism for ILC2 activation in type 2 immunity.

A number of studies have recently identified the epithelium-derived cytokines IL-25 and IL-33 as critical activators of ILC2-mediated innate immunity against parasite infection and responses to allergen challenge. Lack of these cytokines delays the onset of type 2 responses mediated by ILC2s in mouse models. In our studies of human ILC2s, administration of IL-33 initiated cell migration and type 2 cytokine production. IL-25 also induced cytokine production, although the effect on chemotaxis was marginal. However, the efficacy of IL-25 and IL-33 was weaker than that of PGD2 during the tested time points, suggesting that PGD2 could be another important activator of ILC2s. As reported by Barnig et al., combination treatment with PGD2, IL-33, and IL-25 enhanced cytokine production by ILC2s, although no synergistic effect on chemotaxis was seen. Interestingly, activation of CRTH2 strongly upregulated expression of the IL-33 receptor ST2 and moderately upregulated the IL-25 receptor subunit IL-17A. Therefore IL-25, IL-33, and PGD2 could act in concert in ILC2-mediated immune responses.

ILC2s are enriched at sites of inflammation after parasitic infection or allergic challenge, but the mechanism involved in their recruitment remains obscure. IL-33 caused ILC2 migration in a dose-dependent manner, although the efficacy of IL-33 was weaker than that of PGD2. The migration of ILC2s toward PGD2 was completely inhibited by a CRTH2 antagonist, implying that CRTH2 is an important chemoattractant receptor in human ILC2s. Neither IL-25 nor IL-33 potentiated the migration of ILC2s in response to PGD2, suggesting that if the 3 activators coexisted in inflamed tissue, PGD2 could serve as a dominant contributor to the recruitment cascade of ILC2s.

It is well established that activation of ILC2s is characterized by the production of high levels of type 2 cytokines that in turn affect antibody class-switching, recruitment of inflammatory effector cells (eg, eosinophils, basophils, and mast cells), and goblet cell hyperplasia leading to mucus production, all of which contribute to the immune responses to parasite infection, allergen challenge, and tissue damage. In this study we demonstrated that ILC2s are capable of producing many other proinflammatory cytokines after activation, including IL-3, IL-8, IL-21, GM-CSF, and CSF-1. These cytokines could also play important roles in orchestrating ILC2-mediated immune responses. IL-3 can be critical for the growth and differentiation of CD34 progenitor cells into basophils and mast cells and monocytes into dendritic cells. IL-8 is a potent chemokine for neutrophils, cell type that is associated with severe asthma. IL-21 can induce
inflammation in mice through regulation of recruitment of neutrophil and monocyte populations \(^5\), and is also involved in the pathogenesis of allergic disorders and autoimmune diseases (including inflammatory bowel diseases, rheumatoid arthritis, psoriasis, and systemic lupus erythematosus) by controlling the growth, survival, differentiation, and function of T and B cells. \(^5\) GM-CSF and CSF-1 also contribute to allergic and autoimmune diseases. \(^5\) GM-CSF is critical for eosinophil and neutrophil survival and their activities. \(^5\) Overexpression of GM-CSF in mice enhances and anti–GM-CSF antibodies inhibit allergic sensitization and airway inflammation. \(^5\) IL-3 and GM-CSF are coordinately induced with IL-4, IL-5, IL-9, and IL-13, and their genes also cluster on the same chromosome locus, 5q31-33, a major susceptibility locus for asthma and atopy. \(^5\) In contrast, the activation of CRTH2 downregulated gene transcription levels of IFN-γ in ILC2s, suggesting that CRTH2 signaling could potentially favor viral infection. In fact, an unexpected efficacy in reduction of viral infection by one CRTH2 drug has been observed in clinical trials. \(^7\) Therefore through activation of CRTH2, ILC2s might be involved in other as yet unrecognized immune responses.

PGD\(_2\) is the major arachidonic acid metabolite released from mast cells during allergic responses. \(^4\) High concentrations of PGD\(_2\) are detected in the airways of asthmatic patients challenged with allergen, \(^8\) and increased activation of the PGD\(_2\) pathway has been found in patients with severe asthma. \(^9\)

To determine whether CRTH2-mediated activation of ILC2s was functioned under physiologic conditions, we examined the effect on ILC2s of endogenously synthesized PGD\(_2\) from human mast cells. The ILC2 cell responses to mast cell supernatants were similar to those seen to exogenously synthesized PGD\(_2\). The only difference was that some responses to the mast cell supernatants could not be completely blocked by the CRTH2 antagonist or by inhibition of PGD\(_2\) synthesis. This could be caused by the

---

**FIG 6.** Effect of mast cell supernatants on activation of ILC2s (skin) is mediated by CRTH2. A. Levels of PGD\(_2\) and IL-13 in supernatants of mast cells treated with medium (white bars) or IgE/anti-IgE antibody with (black bars) or without (gray bars) diclofenac. Supernatants were assigned as supernatants 1 to 3. B, ILC2 migration after exposure to supernatants with or without TM30089. C and D, mRNA and protein levels of cytokines (Fig 6, C) and mRNA levels of receptors (Fig 6, D) in ILCs after incubation with supernatants with or without TM30089 for 3 hours. * \(P < .05\) (\(n = 2\)).
presence of other active mediators released from activated mast cells in the supernatant, which drive production of specific cytokines. Our data with montelukast suggested that cysLTs are also important ILC2 stimulators. Mast cells are found mainly in epithelial barriers, such as skin and mucosal tissues, and increase in number after exposure to allergens. 1192 In mouse skin ILC2s migrated specifically toward and interacted with skin-resident mast cells, and ILCs were also found in proximity to tissue mast cells in human lungs. 21 Therefore ILC2s can also contribute to mast cell–mediated type 2 immunity. 11 Although multiple stored or de novo–synthesized inflammatory mediators are released from activated mast cells, 9 it is striking that ILC2 migration and type 2 cytokine production in response to mast cell supernatant can be inhibited mostly by CRTH2 antagonism (Fig 6), making it likely that PGD2/CRTH2 serves as a dominant link between activated mast cells and activation of ILC2s. Mast cells orchestrate adaptive type 2 immunity to helminths or allergen through IgE/FceRI-dependent activation. 1 However, mast cells can also be nonspecifically activated in IgE/FceRI-independent ways by substances such as peptides, basic compounds, anaphylatoxins, dextrins, and cytokines. 71-73 Many studies have revealed the critical role of PGD2/CRTH2 in adaptive type 2 immunity, particularly in mast cell–mediated activation of T helper 2 cells and eosinophils. 25,26,28,29,31 Here we further extend their role to the activation of ILC2s. Beyond this, PGD2 production can also be induced by innate responses, such as macrophages activated by double-stranded RNA through Toll-like receptor 3. 74 Therefore ILC2 activation induced by PGD2 could be mediated by either innate or adaptive immune pathways.

Our previous study revealed that the type 2 cytokine production in human ILC2 cells mediated by CRTH2 was markedly enhanced by another group of mast cell mediators, cysLTs. 30 A recent report has described that ILC2s in lungs of mice express CysLT1, which regulates type 2 cytokine production. 75 We have also confirmed the expression of CysLT1 in human ILC2s (data not shown). The combination of TM30089 and montelukast enhanced their inhibitory effect on cytokine production in ILC2s in response to mast cell supernatant. This suggests that CRTH2 and leukotriene receptors could also act synergistically in mast cell–mediated human ILC2 activation. Furthermore, by producing cytokines (IL-3, IL-4, and IL-13), activation of ILC2s could in turn enhance mast cell activation. Given the association with tissue mast cells and allergic skin disease, it might be that the inhibition of PGD2-mediated recruitment and activation of ILC2s through CRTH2 might provide a therapeutic opportunity for atopic dermatitis.

In conclusion, the current study highlights the important proinflammatory role of CRTH2 and its ligand, PGD2, in human ILC2s, and potential roles of ILC2s in IgE/mast cell/CRTH2–mediated adaptive immune cascades. In addition to IL-25 and IL-33, PGD2 is clearly another important and potent driving force in ILC2 activation. It can directly stimulate ILC2s through CRTH2 and can also potentiate IL-25/IL-33–mediated innate responses. Through IgE-mediated mast cell degranulation, ILC2s can contribute to both innate and adaptive type 2 immunity, and through upregulation of IL-33/IL-25 receptors and synergistic interaction with these receptors, CRTH2 plays a pivotal role in bridging innate and adaptive pathways in ILC2s.

We thank Fiona Powrie for critical reading of this manuscript.

Key messages

- PGD2 activates human ILC2s through CRTH2 and induces strong proinflammatory responses, which can serve as a potential therapeutic opportunity for IgE/mast cell/ILC2–mediated allergic inflammation.
- Through sensing IgE-mediated mast cell degranulation, ILC2s can contribute to both innate and adaptive type 2 immunity.
- Through upregulation of IL-33/IL-25 receptors and synergistic interaction to these receptors, CRTH2 plays a pivotal role in bridging innate and adaptive pathways in human ILC2s.

REFERENCES

1. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12:21-7.
2. Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012;30:647-75.
3. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells—how did we miss them? Nat Rev Immunol 2013;13:75-87.
4. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145-9.
5. Neill DR, Wong SH, Bellossi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:1367-70.
6. Koyasu S, Moro K. Innate Th2-type immune responses and the natural helper cell, a newly identified leukocyte population. Curr Opin Allergy Clin Immunol 2011;11:1-14.
7. Neill DR, McKenzie ANJ. Nuocytes and beyond: new insights into helminth expulsion. Trends Parasitol 2011;27:214-21.
8. Hoyler T, Klose CS, Souabni A, Turqueti-Neves A, Pfeifer D, Rawlins EL, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012;37:634-48.
9. Wong SH, Walker JA, Jolin HE, Drynan LF, Hams E, Camelot A, et al. Transcription factor RORα is critical for mucous development. Nat Immunol 2012;13:229-36.
10. Mjosberg J, Bernink J, Peters C, Spits H. Transcriptional control of innate lymphoid cells. Eur J Immunol 2012;42:1916-23.
11. Licona-Limón P, Kim LC, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013;14:536-42.
12. Moro K, Yamada T, Tanabe M, Takeuchi T, Kawasaki T, Kawamoto H, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010;463:540-4.
13. Price AE, Liang HE, Sullivan BM, Rehardt RL, Easley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 2010;107:11489-94.
14. Roediger B, Kyle R, Yip KH, Sumaria N, Goy TV, Kim BS, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 2013;14:564-73.
15. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immuno 2001;15:985-95.
16. Montecelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011;12:1045-54.
17. Chang YJ, Kim HY, Albacker LA, Baumgartn N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011;12:631-8.
18. Barlow JL, Bellossi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airway hyperreactivity. J Allergy Clin Immunol 2012;129:191-8.
19. Klein Wolterink RG, Kleinjan A, van Nimwegen M, Bergen I, de Brujin M, Levani Y, et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012;42:1095-106.

20. Mjøsberg JM, Trifiari S, Cremlyn NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62.

21. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonomogi GF, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013;5:170ra16.

22. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S, et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 2013;5:174ra26.

23. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:526-9.

24. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filgrin skin expression. J Allergy Clin Immunol 2007;120:150-5.

25. Gervais FG, Cruz RP, Chateauneuf AE, Gale S, Sawyer N, Nantel F, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-8.

26. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K. Agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 2002;168:981-5.

27. Nagata K, Hirai H. The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 2003;69:169-77.

28. Tanaka K, Hirai H, Takano S, Nakamura M, Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochim Biophys Acta 2004;1699:1009-14.

29. Xue L, Gyles SL, Wetter FR, Gazi L, Townsend E, Hunter MG, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 2005;175:6531-6.

30. Xue L, Barrow A, Fleming VM, Hunter MG, Ogg G, Klerenan P, et al. Leuko-triene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. J Immunol 2002;158:694-702.

31. Monnerot G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a novel inducer of proinflammatory Th2 cytokine production by Th2 lymphocytes in the presence of IL-3 and IL-4 and differentiates in dendritic cells that produce less IL-12 and shift Th2 cell responses toward a Th2 cytokine pattern. J Immunol 2002;168:6199-207.

32. Henkels KM, Frondorf K, Gonzalez-Mejia ME, Doeff AE, Gomez-Cabrerizo J. IL-9-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett 2011;585:159-66.

33. Hennel ME, Cronin SQ, Ivison S, Piccirillo C, Steiner TS, Levings MK. Human CD4+ FOXP3+ regulatory T cells induce infiltration of dendritic cells that produce less IL-12 and shift Th2 cell responses towards a Th2 cytokine pattern. J Immunol 2002;168:6199-207.

34. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002;169:443-53.

35. Bousniz J, Ouyang A, Oldham E, Song Y, Murphy E, McManus TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;25:479-90.

36. Fallon PG, Ballantine SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of hemithymus expansion. J Exp Med 2006;203:1105-16.

37. Oboki K, Ohno T, Kajiwara N, Arakawa K, Horita I, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010;107:18581-6.

38. Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 1998;392:90-3.

39. Eber P, Soder H, Nguyen VA, Futhart P, Thomas F, Mirtsch P, et al. A novel role for IL-3 in human monocyes cultured in the presence of IL-3 and IL-4, and differentiation towards dendritic cells that produce less IL-12 and shift Th2 cell responses towards a Th2 cytokine pattern. J Immunol 2002;168:6199-207.

40. Henkels KM, Frondorf K, Gonzalez-Mejia ME, Doeff AE, Gomez-Cabrerizo J. IL-9-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett 2011;585:159-66.

41. Hansbro PM, Kaiko GE, Foster PS. Cytokine/anti-cytokine therapy—novel treatments for asthma? Br J Pharmacol 2011;163:81-95.
67. Nowak D, Grimminger F, Jorres R, Oldigs M, Rabe KF, Seeger W, et al. Increased LTB₄ metabolites and PGD₂ in BAL fluid after methacholine challenge in asthmatic subjects. Eur Respir J 1993;6:405-12.

68. Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, Workman R, et al. Release of prostaglandin D₂ into human airways during acute antigen challenge. N Engl J Med 1986;315:800-4.

69. Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et al. Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH₂ inflammation. J Allergy Clin Immunol 2013;131:1504-12.

70. Kawabori S, Kanai N, Tosho T. Proliferative activity of mast cells in allergic nasal mucosa. Clin Exp Allergy 1995;25:173-8.

71. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79.

72. Ferry X, Brehin S, Kamel R, Landry Y. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002;23:1507-15.

73. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006;349:1322-8.

74. Shiraishi Y, Asano K, Niimi K, Fukunaga K, Wakaki M, Kaga J, et al. Cyclooxygenase-2/prostaglandin D₂/CRT1 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J Immunol 2008;180:541-9.

75. Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH₂ cytokine production. J Allergy Clin Immunol 2013;132:205-13.
Lin markers: CD3, CD4, CD8, CD11c, CD11b, FcεRI, CD14, CD19, CD56, CD123

FIG E1. Isotype controls for ILC2 isolation (Fig 1).
FIG E2. Comparison of Lin⁻ CD127⁻ CRTH2⁻ and Lin⁻ CD127⁺ CRTH2⁺ cells from human skin. A, Expression of ST2 (blue line) on CRTH2⁻ cells was much lower than expression on CRTH2⁺ cells. The red line shows unstained cells. B, Lin⁻ CD127⁻ CRTH2⁺ (white columns) but not Lin⁻ CD127⁻ CRTH2⁻ cells (black columns) responded to IL-33 stimulation by IL-13 production (n = 2).
FIG E3. Expression of ST2, IL-17RA, and CRTH2 in ILC2s (skin) is regulated by PGD₂ in a dose-dependent manner. The mRNA level of ST2, CRTH2, IL-17RA, and IL-17RB in the cell pellets of ILC2s after stimulation with various concentrations of PGD₂ is shown. The mRNA levels in the cells treated with 1 nmol/L PGD₂ were treated as 1-fold (n = 2).
FIG E4. CRTH2 mediates proinflammatory cytokine production in ILC2s (skin) in response to supernatants from activated mast cells. Concentrations of IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1 in supernatants after ILC2 incubation with 1:1.5 diluted supernatants of mast cells treated with medium (white bars) or IgE/anti-IgE antibody with (black bars) or without (gray bars) diclofenac in the presence or absence of TM30089 for 3 hours. *P < .05 (n = 2).
FIG E5. Cytokine production by ILC2s (skin) in response to supernatants from activated mast cells is inhibited by CysLT₁ antagonist partially but not by D prostanoid receptor antagonist. The effects of TM30089, BWA868C, montelukast, and their combination on the production of IL-13 (protein), IL-3, and GM-CSF (mRNA) in ILC2s treated with the supernatant from IgE/anti-IgE-activated mast cells (gray bars) were examined with ELISA or quantitative RT-PCR (n = 1).
| Antigen | Clone       | Supplier                                      |
|---------|-------------|-----------------------------------------------|
| CD3     | SK7         | BD Biosciences, San Jose, Calif               |
| CD19    | SJ25C1      | BD Biosciences                               |
| CD123   | FAB301C     | R&D Systems, Minneapolis, Minn                |
| CD11b   | DC151/18    | Abcam, Cambridge, United Kingdom              |
| CD11c   | BU15        | Abcam                                         |
| CD8     | RPA-T8      | BioLegend, San Diego, Calif                  |
| FcεRI   | AER-37 (CRA-1) | BioLegend                                 |
| CD14    | Mep9        | BD Biosciences                               |
| CD4     | MEM-241     | Abcam                                         |
| CD45    | H130        | BioLegend                                     |
| CD56    | B159        | BioLegend                                     |
| CRTH2   | BM16        | Miltenyi Biotec, Bergisch Gladbach, Germany   |
| IL-7Rx  | A019D5      | BioLegend                                     |
| ST2     | Ab72778     | Abcam                                         |
| Gene  | Primer 1                  | Primer 2                  | Probe no. |
|-------|--------------------------|--------------------------|-----------|
| IL4   | 5'-CACCAGTTGCCGTAACAG-3'  | 5'-GCCCTGAGAAAGTTTCC-3'  | 16        |
| IL5   | 5'-GGTTGGCAGCCAAAGAT-3'   | 5'-TCATTCTCATTCTC-3'      | 25        |
| IL13  | 5'-AGCCCTCGGAGCTCAT-3'    | 5'-CTCCATACCATGTCG-3'     | 17        |
| IL17A | 5'-TGGGAAGACCTCATTGTG-3'  | 5'-GGATTTCTGGGATTGTG-3'   | 8         |
| IL17F | 5'-GGAATCATCAATGAAAACCA-3' | 5'-TGGGTTCCAGTGACAG-3'    | 10        |
| IFNG  | 5'-GGCATTTGGAATGGAAAG-3'  | 5'-TTTGGAAGCTCTGCACTTT-3' | 21        |
| CRTH2 | 5'-CCTGGTGTCCCTCTGTGC-3'  | 5'-TCTGGGAGACGCTCATCTG-3' | 43        |
| IL1RL1| 5'-TTGTCTACCAATTGACCTCTACAAC-3' | 5'-GATCCCTGGAAGCCTGCAAC-3' | 56        |
| IL17RA| 5'-CATCCATGCTCATCTGC-3'   | 5'-GCCATCGGTGATTTGGTGT-3' | 85        |
| IL17RB| 5'-GCCCTCCATGTCGTGAAAT-3' | 5'-CCGGCTCTGACACACTTT-3'  | 64        |
| GAPDH | 5'-AGCCATCGCTCAGACAC-3'   | 5'-GCCCAATAGGACCAATCTC-3' | 60        |

GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.